Risk of Viral Failure Declines With Duration of Suppression on Highly Active Antiretroviral Therapy Irrespective of Adherence Level
Journal of Acquired Immune Deficiency Syndromes - United States
doi 10.1097/qai.0b013e3181f2ac87
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2010
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)